Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02694913 · ClinicalTrials.gov registry record
Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 82
- Enrollment target
NCT02694913: Completed study, sponsored by Weill Medical College of Cornell University.
NCT02694913 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02694913 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
This is a non-interventional, R01-funded pilot study that will identify serum and cellular markers in patients' blood samples that can be used as short-term biomarkers of rituximab response. We hypothesize that serum complement levels, activation of natural killer cells, and clearance of peripheral B-cells will be accurate biomarkers of rituximab response, and may be correlated with long-term outcomes.
Interventions
- OTHER Non Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2015-11 |
| Est. Completion | 2019-02-07 |
What the finished NCT02694913 record still lists
NCT02694913 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Non Interventional is the first listed.
NCT02694913 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02694913 about?
NCT02694913 is a clinical study titled "Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies". This is a non-interventional, R01-funded pilot study that will identify serum and cellular markers in patients' blood samples that can be used as short-term biomarkers of rituximab response. We hypothesize that serum complement levels, activation of natural killer cells, and clearance of peripheral ...
What is the current status of trial NCT02694913?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2015-11. Estimated completion is 2019-02-07.
What interventions are being tested in trial NCT02694913?
The interventions under investigation include: Non Interventional (OTHER).
Who is sponsoring clinical trial NCT02694913?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia